Traditional Chinese medicine composition for preventing and treating pregnancy toxemia and compound preparation

Abstract

The invention belongs to the technical field of veterinary traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for preventing and treating pregnancy toxemia and a compound preparation. The traditional Chinese medicine composition for preventing and treating pregnancy toxemia comprises the following raw materials in parts by weight: codonopsis pilosula, astragalus membranaceus, angelica sinensis, radix rehmanniae preparata, ligusticum wallichii and liquorice. The traditional Chinese medicine composition for preventing and treating the pregnancy toxemia can effectively treat the pregnancy toxemia, and after being combined with propylene glycol for use, the traditional Chinese medicine composition has the advantages that raw materials are easy to obtain, the preparation process is simple, administration is simple and easy to operate, toxic and side effects are low, veterinary drug residues are few, the effect taking speed is high, and the effect is good. The invention provides an effective way for preventing and treating the pregnancy toxemia.

Description

Technical Field

[0001] This invention belongs to the technical field of veterinary Chinese medicine composition, specifically relating to a Chinese medicine composition and compound preparation for the prevention and treatment of pregnancy toxemia. Background Technology

[0002] Pregnancy toxemia is a common metabolic disease in ewes during late pregnancy, with negative energy balance as its core cause. Clinical symptoms include hypoglycemia, hyperketosis, and fatty liver. Pregnancy toxemia seriously threatens the health of ewes and lambs, causing significant economic losses to the livestock industry.

[0003] Currently, the main treatment for pregnancy toxemia is propylene glycol as a glucogenin precursor. However, this method has the problem of limited efficacy and being more of a symptomatic treatment than a cure. In addition, there are technical records of using traditional Chinese medicine combinations to treat pregnancy toxemia in ewes. Although this method can regulate the metabolism of ewes, it is relatively slow to take effect and is difficult to effectively inhibit the development of pregnancy toxemia in ewes.

[0004] Therefore, how to provide a fast-acting and effective composition for the prevention and treatment of pregnancy toxemia in ewes has become a problem that needs to be solved in this field. Summary of the Invention

[0005] To address the lack of effective and rapid methods for preventing and treating pregnancy toxemia in ewes in existing technologies, this invention provides a traditional Chinese medicine composition and compound preparation for the prevention and treatment of pregnancy toxemia, specifically including the following technical solutions: This invention provides a traditional Chinese medicine composition for the prevention and treatment of pregnancy toxemia. The raw materials of the traditional Chinese medicine composition, by weight, include: 25-35 parts of Codonopsis pilosula, 25-35 parts of Astragalus membranaceus, 25-35 parts of Angelica sinensis, 25-35 parts of Rehmannia glutinosa, 15-25 parts of Ligusticum chuanxiong, and 15-25 parts of Glycyrrhiza uralensis.

[0006] The present invention also provides a method for preparing the traditional Chinese medicine composition as described above, comprising the following steps: The raw materials of the traditional Chinese medicine composition are mixed and soaked in cold water to obtain a raw material mixture; After mixing the raw material mixture with water, simmer the medicine over low heat for 15-20 minutes. After simmering, filter to obtain the medicinal liquid. The medicinal solution is concentrated until the concentration reaches 0.5~1.5g / mL to obtain the traditional Chinese medicine composition.

[0007] Preferably, the raw material mixture and water are mixed at a volume ratio of 1:4 to 6.

[0008] Preferably, the concentration process includes rotary evaporation concentration; the conditions for rotary evaporation concentration are 60~80 ℃ and 60~80 rpm.

[0009] The present invention also provides a compound preparation for the prevention and treatment of preeclampsia, the raw materials of which include a traditional Chinese medicine composition and propylene glycol, wherein the traditional Chinese medicine composition is the traditional Chinese medicine composition as described above or a traditional Chinese medicine composition prepared by the preparation method described above; the mass ratio of the traditional Chinese medicine composition to propylene glycol is 210~230:25.9~36.3.

[0010] The present invention also provides a method for preparing the compound preparation as described above, comprising the following steps: The traditional Chinese medicine composition is mixed with propylene glycol to obtain the compound preparation.

[0011] The present invention also provides the application of the traditional Chinese medicine composition, the traditional Chinese medicine composition prepared by the preparation method, the compound preparation or the compound preparation prepared by the preparation method as described above in the prevention and treatment of pregnancy toxemia in livestock.

[0012] Preferably, the livestock includes sheep.

[0013] Preferably, the prevention and treatment of pregnancy toxemia in livestock includes any one or more of the following aspects: 1) Lower blood ketone levels; 2) Reduce triglyceride levels; 3) Reduce total protein content; 4) Reduce albumin levels; 5) Reduce creatinine levels; 6) Reduce amylase content; 7) Reduce the content of non-esterified fatty acids; 8) Increase glucagon levels; 9) Increase insulin levels; 10) Increase fructosamine content.

[0014] Preferably, the dosage of the compound preparation is 200-300 mL / time / day, and the course of treatment is ≥3 days.

[0015] The beneficial effects of this invention are as follows: This invention discloses a traditional Chinese medicine composition for preventing and treating pregnancy toxemia. The raw materials of the composition, by weight, include Codonopsis pilosula, Astragalus membranaceus, Angelica sinensis, Rehmannia glutinosa, Ligusticum chuanxiong, and Glycyrrhiza uralensis. This traditional Chinese medicine composition for preventing and treating pregnancy toxemia is effective in treating pregnancy toxemia, and the raw materials are readily available and the preparation method is simple. When combined with propylene glycol, this traditional Chinese medicine composition has the following advantages compared to other traditional Chinese medicine or Western veterinary drugs for treating pregnancy toxemia: 1) Simple administration, the prepared veterinary drug can be directly administered orally; 2) Low toxicity and side effects, the toxicity and side effects of the combination of the traditional Chinese medicine composition and propylene glycol are significantly reduced, and veterinary drug residues are low; 3) Rapid onset of action, blood ketone levels in sheep treated with pregnancy toxemia by the combination of the traditional Chinese medicine composition and propylene glycol decrease to normal levels within 4 days. In summary, this invention provides an effective way to prevent and treat pregnancy toxemia. Attached Figure Description

[0016] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0017] Figure 1 This refers to the results of a blood ketone test. Among them, different lowercase letters in each row of data in the three-line table indicate significant differences (P<0.05). Detailed Implementation

[0018] This invention provides a traditional Chinese medicine composition for the prevention and treatment of pregnancy toxemia. The raw materials of the traditional Chinese medicine composition, by weight, include: 25-35 parts of Codonopsis pilosula, 25-35 parts of Astragalus membranaceus, 25-35 parts of Angelica sinensis, 25-35 parts of Rehmannia glutinosa, 15-25 parts of Ligusticum chuanxiong, and 15-25 parts of Glycyrrhiza uralensis.

[0019] In one embodiment, the raw materials of the traditional Chinese medicine composition preferably include 27-32 parts of Codonopsis pilosula, 27-32 parts of Astragalus membranaceus, 27-32 parts of Angelica sinensis, 27-32 parts of Rehmannia glutinosa, 17-22 parts of Ligusticum chuanxiong, and 17-22 parts of Glycyrrhiza uralensis. In another embodiment, the raw materials of the traditional Chinese medicine composition are preferably: 30 parts of Codonopsis pilosula, 30 parts of Astragalus membranaceus, 30 parts of Angelica sinensis, 30 parts of Rehmannia glutinosa, 20 parts of Ligusticum chuanxiong, and 20 parts of Glycyrrhiza uralensis.

[0020] In the traditional Chinese medicine composition of the present invention, Codonopsis pilosula and Astragalus membranaceus are used as principal herbs to tonify qi and strengthen the spleen, and to predominantly prevent and treat pregnancy toxemia in ewes; Angelica sinensis and Rehmannia glutinosa are used as assistant herbs to nourish blood and assist the principal herbs in enhancing the effect of tonifying both qi and blood; Ligusticum chuanxiong is used as adjuvant herbs to invigorate blood and promote qi circulation, to counteract the cloying nature of the tonifying herbs, and to promote the circulation of qi and blood; Glycyrrhiza uralensis is used as guiding herbs to harmonize the herbs and guide them to their respective meridians.

[0021] Furthermore, in the traditional Chinese medicine composition of this invention, Codonopsis pilosula contains lobetyolin; Astragalus membranaceus contains astragaloside IV and calycosin-7-glucoside; lobetyolin, along with astragaloside IV and calycosin-7-glucoside, constitute the core unit for replenishing qi and regulating energy metabolism. This enhances the body's immune function, improves the utilization efficiency of energy substances (such as glucose), and corrects metabolic disorders caused by negative energy balance in late pregnancy. Angelica sinensis contains ferulic acid and ligustilide; Ligusticum chuanxiong contains ferulic acid and tetramethylpyrazine / chuanxiongzine; ferulic acid, tetramethylpyrazine, and ligustilide are the main active substances for promoting blood circulation and removing blood stasis, improving microcirculation by dilating peripheral blood vessels. Rehmannia glutinosa contains catalpol and acteoside; catalpol and acteoside have the effects of nourishing yin and replenishing blood, acting on the hematopoietic system, promoting red blood cell production, and improving the blood deficiency state caused by insufficient hepatic gluconeogenesis and excessive nutrient consumption. Glycyrrhiza uralensis contains liquiditin and glycyrrhizic acid. Glycyrrhetinic acid and glycyrrhetinic acid work together to harmonize various drugs and detoxify and protect the liver. These active ingredients work together to regulate energy metabolism, improve microcirculation disorders, promote hematopoietic function, and protect liver function.

[0022] The present invention also provides a method for preparing the traditional Chinese medicine composition as described above, comprising the following steps: The raw materials of the traditional Chinese medicine composition are mixed and soaked in cold water to obtain a raw material mixture; the raw material mixture is mixed with water and simmered over low heat for 15-20 minutes. After simmering, the mixture is filtered to obtain a medicinal liquid; the medicinal liquid is concentrated until the concentration reaches 0.5-1.5 g / mL to obtain the traditional Chinese medicine composition.

[0023] This invention involves mixing the raw materials of a traditional Chinese medicine composition and soaking them in cold water to obtain a raw material mixture. In one embodiment, the amount of cold water added is such that the water level completely covers the raw materials of the traditional Chinese medicine composition. Soaking in cold water allows the dried medicinal materials to fully absorb water and swell, laying the foundation for the dissolution of effective components in the subsequent decoction stage.

[0024] After obtaining the raw material mixture, this invention mixes the raw material mixture with water and simmers it over low heat for 15-20 minutes. After simmering, the mixture is filtered to obtain the medicinal liquid. In one embodiment, the raw material mixture and water are mixed at a volume ratio of 1:4-6. In another embodiment, the volume ratio of the raw material mixture to water can be 1:4, 1:5, or 1:6. In a specific embodiment, the volume ratio of the raw material mixture to water is 1:5. In one embodiment, the simmering time is 15-20 minutes. In another embodiment, the simmering time can be 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, or 20 minutes. In one embodiment, the filtration is performed while the liquid is still hot. The limitations on the volume of the raw material mixture and water, as well as the limitations on the simmering operation, effectively reduce the destruction and loss of active ingredients and ensure batch-to-batch quality stability and process efficiency. Hot filtration prevents precipitation due to decreased solubility of colloids and tannins after the medicinal liquid cools, thus avoiding loss of active ingredients.

[0025] After obtaining the medicinal liquid, the present invention concentrates the medicinal liquid until the concentration reaches 0.5~1.5g / mL to obtain the traditional Chinese medicine composition. As one embodiment, the concentration method includes rotary evaporation concentration. As one embodiment, the rotary evaporation concentration conditions are 60~80℃ and 60~80 rpm. As one embodiment, the rotary evaporation temperature can be any one or any two values ​​between 60℃, 65℃, 70℃, 75℃, and 80℃; as one embodiment, the rotary evaporation speed can be any one or any two values ​​between 60rpm, 65rpm, 70rpm, 75rpm, and 80rpm. In one implementation method, the concentration of the drug solution can be any one or an intermediate value between any two of the following: 0.5 g / mL, 0.6 g / mL, 0.7 g / mL, 0.8 g / mL, 0.9 g / mL, 1.0 g / mL, 1.1 g / mL, 1.2 g / mL, 1.3 g / mL, 1.4 g / mL, and 1.5 g / mL. This invention protects heat-sensitive components and prevents decomposition and inactivation by controlling the temperature gently during concentration. Standardizing the concentration endpoint to 0.5~1.5 g / mL is a key quality control step to ensure a constant content of active ingredients in each batch of product, precise compatibility with propylene glycol, and accurate and reliable dosage.

[0026] The present invention also provides a compound preparation for the prevention and treatment of preeclampsia, the raw materials of which include a traditional Chinese medicine composition and propylene glycol, wherein the traditional Chinese medicine composition is the traditional Chinese medicine composition as described above or a traditional Chinese medicine composition prepared by the preparation method described above; the mass ratio of the traditional Chinese medicine composition to propylene glycol is 210~230:25.9~36.3.

[0027] In one embodiment, the mass ratio of the traditional Chinese medicine composition to propylene glycol is 210-230:25.9-36.3. In another embodiment, the mass ratio of the traditional Chinese medicine composition to propylene glycol can be any one of 210:25.9, 220:31.1, and 230:36.3, or an intermediate value between two of these values. In another embodiment, when the traditional Chinese medicine composition has a concentration of 1 g / mL, a mass ratio of 210-230:25.9-36.3 to propylene glycol is equivalent to a volume ratio of 210-230:25-35. In a specific embodiment, the volume ratio of the traditional Chinese medicine composition with a concentration of 1 g / mL to propylene glycol is 220:30. In another embodiment, the dosage form of the compound preparation is a liquid preparation. The final product of this invention is a clear liquid preparation ranging from brown to dark brown; it has a slightly fragrant odor and a sweet and slightly bitter taste. Its relative density at 20°C should be in the range of 1.08 to 1.18, and its pH value should be in the range of 5.5 to 6.5. The advantage of combining the traditional Chinese medicine composition with propylene glycol for better efficacy lies in the following: propylene glycol can rapidly raise blood sugar, reduce the body's breakdown of fat and the production of blood ketones, ensuring that the blood ketone levels in pregnant ewes with preeclampsia drop to normal levels within a short period. Meanwhile, the traditional Chinese medicine composition can inhibit fat mobilization, improve liver metabolism, and clear ketone bodies from the body, fundamentally correcting the abnormality of ketogenic metabolism and preventing recurrence of the condition. The compound preparation lowers ketones faster and has a more stable therapeutic effect. The synergistic effect of both on the body achieves a dual effect of external function and internal metabolic regulation, resulting in a better therapeutic effect than single therapy.

[0028] The present invention also provides a method for preparing the compound preparation as described above, comprising the following steps: The traditional Chinese medicine composition is mixed with propylene glycol to obtain the compound preparation.

[0029] This invention establishes a fixed ratio for the optimal synergistic therapeutic effect of compound traditional Chinese medicine and propylene glycol. This precise ratio facilitates standardized operation and quality control, and is crucial for ensuring the stable and reproducible effectiveness of the rapid ketone-lowering and synergistic effects of the "Combined Treatment Group (CHM-PG)" in experiments.

[0030] As one implementation method, after obtaining the compound preparation, the process further includes a step of sealing and refrigerating it. This storage condition effectively inhibits microbial growth and slows down potential chemical changes, significantly extending the product's shelf life and ensuring the stability and safety of its efficacy during clinical use.

[0031] The present invention also provides the application of the traditional Chinese medicine composition, the traditional Chinese medicine composition prepared by the preparation method, the compound preparation or the compound preparation prepared by the preparation method as described above in the prevention and treatment of pregnancy toxemia in livestock.

[0032] In one embodiment, the livestock includes ruminants. In one embodiment, the ruminants include sheep. In one embodiment, the prevention and treatment of pregnancy toxemia in livestock includes any one or more of the following aspects: 1) reducing blood ketone levels; 2) reducing triglyceride levels; 3) reducing total protein levels; 4) reducing albumin levels; 5) reducing creatinine levels; 6) reducing amylase levels; 7) reducing non-esterified fatty acid levels; 8) increasing glucagon levels; 9) increasing insulin levels; 10) increasing fructosamine levels.

[0033] As one implementation method, the dosage of the compound preparation is 200-300 mL / time / day, with a treatment course of ≥3 days. As another implementation method, the dosage of the compound preparation can be any one of 200 mL / time / day, 250 mL / time / day, and 300 mL / time / day, or an intermediate value between two of these values. In a specific embodiment, the dosage of the compound preparation is 250 mL / time / day. As one implementation method, when livestock take the compound preparation for 3 days, various indicators of pregnancy toxemia show significant improvement. As one implementation method, the compound preparation is administered orally.

[0034] To further illustrate the present invention, the following detailed description, in conjunction with the accompanying drawings and embodiments, describes a traditional Chinese medicine composition and compound preparation for the prevention and treatment of preeclampsia provided by the present invention, but these descriptions should not be construed as limiting the scope of protection of the present invention.

[0035] Table 1 Source of Raw Materials

[0036] The source of the raw materials described in this invention is not a necessary condition, but is merely an example to illustrate the technical solution. In principle, the above-mentioned raw materials can all be replaced by similar products produced in other places or by other companies.

[0037] Example 1: Oral dosage of the traditional Chinese medicine composition and oral dosage of propylene glycol based on 1) Oral dosage of traditional Chinese medicine composition The oral dosage of the traditional Chinese medicine composition of this invention is calculated using the body surface area (BSA) method for humans and animals. The BSA of sheep can be estimated using the following Meeh-Rubner formula: ; W represents body weight (in grams). K is the body size coefficient, with values ​​of 10.6 for humans, 10 for sheep, 10.1 for rabbits, 11.2 for dogs, and 9.1 for mice (generally accepted values ​​from the literature).

[0038] Calculated based on the body surface area of ​​sheep weighing 50kg~55kg: ; 2) Equivalent dose conversion: ; Substitute into the formula: ; The human dosage is 160g, which is derived from the combination of the Chinese herbal medicines of this invention (Codonopsis pilosula 30g, Astragalus membranaceus 30g, Angelica sinensis 30g, Rehmannia glutinosa 30g, Ligusticum chuanxiong 20g, Glycyrrhiza uralensis 20g).

[0039] 3) Oral dosage of propylene glycol: When treating pregnancy toxemia in sheep with propylene glycol, literature and clinical practice indicate that the safe single oral dose of propylene glycol for sheep and goats generally does not exceed 0.5 g / kg to 1 g / kg (25 g / kg to 50 g / kg).

[0040] In clinical trials, this invention takes into account individual differences and the severity of the disease, and selects 220ml of the traditional Chinese medicine composition and 30ml of propylene glycol as the daily dosage within the safe dosage range of the traditional Chinese medicine composition and propylene glycol stock solution.

[0041] Example 2: A traditional Chinese medicine composition for preventing and treating preeclampsia and its preparation method The raw materials of the traditional Chinese medicine composition are: Codonopsis pilosula 25g, Astragalus membranaceus 25g, Angelica sinensis 25g, Rehmannia glutinosa 25g, Ligusticum chuanxiong 15g, Glycyrrhiza uralensis 15g.

[0042] The preparation method of the traditional Chinese medicine composition is as follows: ① Soaking: After weighing each raw material according to the dosage, mix all the raw materials in the Chinese herbal composition to obtain a mixture. Add cold water to the mixture until the water level is higher than the surface of the herbs, and soak for 12 hours to obtain the raw material mixture.

[0043] ②Decoction of medicine: The raw material mixture and water are mixed at a volume ratio of 1:5, and the mixture is simmered over low heat for 20 minutes using a decoction machine. The mixture is then filtered while hot to remove the dregs and obtain the medicinal liquid.

[0044] ③ Concentration: The medicinal liquid was injected into a rotary evaporator flask and concentrated using a rotary evaporator. The conditions of the rotary evaporator were set to 70°C and 70 rpm. The liquid was evaporated until the concentration of the medicinal liquid reached 1 g / mL to obtain the traditional Chinese medicine composition.

[0045] Example 3: A traditional Chinese medicine composition for preventing and treating preeclampsia and its preparation method The raw materials of the traditional Chinese medicine composition are: Codonopsis pilosula 30g, Astragalus membranaceus 30g, Angelica sinensis 30g, Rehmannia glutinosa 30g, Ligusticum chuanxiong 20g, Glycyrrhiza uralensis 20g.

[0046] The preparation method of the traditional Chinese medicine composition is the same as in Example 1.

[0047] Example 4: A traditional Chinese medicine composition for preventing and treating preeclampsia and its preparation method The raw materials of the traditional Chinese medicine composition are: Codonopsis pilosula 35g, Astragalus membranaceus 35g, Angelica sinensis 35g, Rehmannia glutinosa 35g, Ligusticum chuanxiong 25g, Glycyrrhiza uralensis 25g.

[0048] The preparation method of the traditional Chinese medicine composition is the same as in Example 1.

[0049] Example 5: A compound preparation for the prevention and treatment of preeclampsia and its preparation method The compound preparation includes a traditional Chinese medicine composition and propylene glycol.

[0050] The mass ratio of the traditional Chinese medicine composition to propylene glycol is 220:31.1, which is equivalent to a volume ratio of 220:30.

[0051] The preparation method of the compound preparation is as follows: The traditional Chinese medicine composition and propylene glycol are mixed in a certain proportion to obtain the compound preparation. The compound preparation is then placed in a sealed container and stored under cold storage for later use.

[0052] For short-term (≤7 days) refrigerated storage, it can be stored at 4°C. For long-term (>7 days) storage, it needs to be frozen at -20°C.

[0053] Example 6: Effect Verification Experiment (1) Grouping of experimental animals: Seven healthy Hu sheep (healthy sheep are defined as those with a blood ketone content <0.7mmol / L) were selected from pregnant ewes in large-scale farms to serve as the blank control group (NC).

[0054] Twenty-eight Hu sheep diagnosed with pregnancy toxemia (PT) were selected from pregnant ewes in large-scale farms (diagnosed PT sheep were defined as having blood ketone content >0.7mmol / L). They were randomly divided into four groups of seven each. The four groups were: model control group (PT), traditional Chinese medicine treatment group (CHM), propylene glycol treatment group (PG), and combined treatment group (CHM-PG).

[0055] (2) Administration of drugs to experimental animals Prepare a traditional Chinese medicine composition according to the contents of Example 2 for later use; then prepare a compound preparation according to the contents of Example 4 for later use.

[0056] The treatment methods for each group of experimental animals are as follows: NC group: 250 mL of normal saline was administered orally daily for 3 consecutive days; PT group: 250 mL of normal saline was administered orally daily for 3 consecutive days; CHM group: 250 mL of the traditional Chinese medicine composition was administered orally daily for 3 consecutive days; CHM group: 250 mL of compound preparation was administered orally daily for 3 consecutive days; PG group: Dissolve 30 mL of propylene glycol stock solution with a content of ≥99.0% in 220 mL of physiological saline, and administer 250 mL of malondialdehyde physiological saline mixture orally every day for 3 consecutive days; CHM-PG group: 250mL of the compound preparation was administered orally daily for 3 consecutive days.

[0057] (3) Collection of test animal samples After oral administration, blood samples were collected from the jugular veins on both sides of the ewe and placed into three types of blood collection tubes (additive-free blood collection tubes, EDTA anticoagulant tubes, and heparin sodium anticoagulant tubes) to separate serum and plasma for later testing.

[0058] (4) Inspection content 1) Blood ketone level test Using a ketone body analyzer and test strips, first insert the test strip into the blood ketone analyzer. When the device screen displays a flashing teardrop symbol, use a disposable blood collection device to collect a drop of blood close to the test strip until a horizontal line appears on the screen. Remove the device and wait a few seconds for the value to be automatically displayed on the screen before recording the result.

[0059] 2) Plasma biochemical testing After mixing the blood sample in the heparin sodium anticoagulant tube by inverting it, the plasma was separated by centrifugation at 2500 rpm for 10 min and analyzed using a fully automated biochemical analyzer.

[0060] 3) Serum enzyme-linked immunosorbent assay After the blood sample from the additive-free blood collection tube was allowed to stand for 12 hours, the serum was separated by centrifugation at 2500 rpm for 10 minutes, and the relevant indicators were detected according to the ELISA kit instructions.

[0061] (5) Test results 1) Blood ketone test results Blood ketone test results as follows Figure 1 As shown in Table 2, the serum ketone levels in the NC group, CHM group, PG group, and CHM-PG group were all ≤0.7 mmol / L on day 3 of treatment. The serum ketone levels in the CHM, PG, and CHM-PG groups showed a decreasing trend after treatment. Specifically, the serum ketone levels in the PG and CHM-PG groups were already below 0.7 mmol / L on day 2 of treatment, and reached a plateau on day 3. During the treatment process, the CHM-PG group showed the fastest decrease in serum ketone levels compared to the other treatment groups, indicating that the CHM-PG group had the best treatment effect, and that CHM and PG could produce a synergistic therapeutic effect.

[0062] Table 2. Blood Ketone Test Results

[0063] Note: In Table 2, different lowercase letters in the superscript of the same row indicate significant differences (P<0.05).

[0064] 2) Plasma biochemical test results The plasma biochemical test results are shown in Table 3. It can be seen that all treatment groups had a significant regulatory effect on indicators related to preeclampsia. The triglyceride (TG) content in the PT group was significantly higher than that in the other groups (P<0.01), while the TG content in the CHM and PG groups was significantly lower (P<0.05), indicating that single therapy can effectively alleviate hyperlipidemia. The TG content in the CHM-PG group was not significantly different from that in the PT group, but combined with the blood glucose and ketone test results, this phenomenon suggests that the combined therapy may have significantly promoted the breakdown and metabolism of hepatic fat. Regarding indicators characterizing dehydration, the total protein (TP) and albumin (ALB) content in the PT group was significantly increased (P<0.05), while the content in the PG and CHM-PG groups was significantly decreased (P<0.05), with the CHM-PG group showing the lowest values, indicating that it was most effective in correcting dehydration. Meanwhile, the creatinine (CREA) level in the PT group was significantly elevated (P<0.05), indicating impaired renal function in the sheep diagnosed with preeclampsia, while the CREA levels in the PG and CHM-PG groups were significantly decreased (P<0.05), indicating improved renal function in the PG and CHM-PG groups. The amylase (AMY) level in the PT group was significantly higher than in other groups (P<0.05), while the TG levels in the CHM and PG groups were significantly lower (P<0.05), indicating that monotherapy can effectively alleviate energy metabolism disorders. There was no significant difference in TG levels between the CHM-PG and PT groups. The lipid (LIP) level in the NC group was significantly higher than in other groups (P<0.05), indicating normal lipid metabolism.

[0065] In summary, both the CHM-PG group and the PG group showed efficacy in regulating lipid metabolism and improving renal function, with the CHM-PG group exhibiting the best effect in correcting homeostasis.

[0066] Table 3. Results of biochemical tests on sheep serum

[0067] Note: In Table 3, different uppercase letters in the same row headings indicate extremely significant differences (P<0.01), and different lowercase letters indicate significant differences (P<0.05).

[0068] 3) Serum enzyme-linked immunosorbent assay (ELISA) results The results of the serum enzyme-linked immunosorbent assay are shown in Table 4. It can be seen that each treatment group had a very significant regulatory effect on hormones and metabolic indicators related to preeclampsia.

[0069] In terms of key energy metabolism indicators, compared with the PT group, both the PG group and the CHM-PG group significantly reduced serum free fatty acid content (P<0.05), and the CHM-PG group showed the most significant effect with the lowest value, indicating that the two treatment methods, especially the combined therapy, can effectively inhibit fat mobilization and alleviate negative energy balance from the source.

[0070] Regarding the core hormones regulating blood glucose balance, the glucagon levels in the PG and CHM-PG groups were significantly higher than in other groups (P<0.01), with the CHM-PG group showing a significantly higher level than the PG group. This indicates that propylene glycol strongly stimulates the body's glucagon response, and the addition of the compound traditional Chinese medicine has a further amplifying effect. Correspondingly, insulin levels in both groups showed the same trend, with the CHM-PG group showing a significantly higher insulin level than the PG group (P<0.01), and the PG group showing a significantly higher level than other groups (P<0.01). This indicates that when glucagon drives gluconeogenesis, insulin secretion increases synergistically to maintain blood glucose homeostasis. This result is corroborated by the fact that the CHM-PG group had the highest fructosamine level (P<0.05), jointly confirming that the combined treatment regimen is the most effective in improving mid-term blood glucose levels.

[0071] In summary, the data show that propylene glycol, as a gluconeogenic precursor, is key to rapidly initiating gluconeogenesis and improving hypoglycemia. When combined with compound traditional Chinese medicine, it exhibits a significant synergistic effect in inhibiting fat mobilization, promoting gluconeogenesis, and improving overall blood glucose levels.

[0072] Table 4 Results of Enzyme-Linked Immunosorbent Assay

[0073] Note: In Table 4, different uppercase letters in the same row headings indicate extremely significant differences (P<0.01), and different lowercase letters indicate significant differences (P<0.05).

[0074] In summary, this invention provides a compound preparation for the prevention and treatment of pregnancy toxemia. Compared with other traditional Chinese medicine or Western veterinary drugs used to treat pregnancy toxemia, the preparation process of this compound preparation is simple and easy to operate; it only requires mixing the prepared compound preparation with commercially available propylene glycol. Administration is also simple, as the prepared veterinary drug can be directly administered orally. Furthermore, it has low toxicity and side effects; compared with Western veterinary drugs, the toxicity and side effects of the compound preparation combined with propylene glycol are significantly reduced, resulting in low drug residues. Experiments have shown that the blood ketone levels in sheep treated with pregnancy toxemia using the traditional Chinese medicine combination with propylene glycol decreased to normal levels within 4 days. This invention provides an effective way to prevent and treat pregnancy toxemia.

[0075] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, not all embodiments. People can obtain other embodiments without creative effort, as shown in these embodiments, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A traditional Chinese medicine composition for preventing and treating preeclampsia, characterized in that, The raw materials of the traditional Chinese medicine composition, by weight, include: 25-35 parts of Codonopsis pilosula, 25-35 parts of Astragalus membranaceus, 25-35 parts of Angelica sinensis, 25-35 parts of Rehmannia glutinosa, 15-25 parts of Ligusticum chuanxiong, and 15-25 parts of Glycyrrhiza uralensis.

2. The method for preparing the traditional Chinese medicine composition according to claim 1, characterized in that, Includes the following steps: The raw materials of the traditional Chinese medicine composition are mixed and soaked in cold water to obtain a raw material mixture; After mixing the raw material mixture with water, simmer the medicine over low heat for 15-20 minutes. After simmering, filter to obtain the medicinal liquid. The medicinal solution is concentrated until the concentration reaches 0.5~1.5g / mL to obtain the traditional Chinese medicine composition.

3. The preparation method according to claim 2, characterized in that, The raw material mixture and water are mixed at a volume ratio of 1:4 to 6.

4. The preparation method according to claim 2, characterized in that, The concentration process includes rotary evaporation concentration; the conditions for rotary evaporation concentration are 60~80 ℃ and 60~80 rpm.

5. A compound preparation for the prevention and treatment of preeclampsia, characterized in that, The raw materials include a traditional Chinese medicine composition and propylene glycol, wherein the traditional Chinese medicine composition is the traditional Chinese medicine composition according to claim 1 or the traditional Chinese medicine composition prepared by the preparation method according to any one of claims 2 to 4; The mass ratio of the traditional Chinese medicine composition to propylene glycol is 210~230:25.9~36.

3.

6. The method for preparing the compound preparation according to claim 5, characterized in that, Includes the following steps: The traditional Chinese medicine composition is mixed with propylene glycol to obtain the compound preparation.

7. The use of the traditional Chinese medicine composition according to claim 1, the traditional Chinese medicine composition prepared by the preparation method according to any one of claims 2 to 4, the compound preparation according to claim 5, or the compound preparation prepared by the preparation method according to claim 6 in the prevention and treatment of pregnancy toxemia in livestock.

8. The application as described in claim 7, characterized in that, The livestock mentioned include sheep.

9. The application as described in claim 7, characterized in that, The prevention and treatment of pregnancy toxemia in livestock includes any one or more of the following aspects: 1) Lower blood ketone levels; 2) Reduce triglyceride levels; 3) Reduce total protein content; 4) Reduce albumin levels; 5) Reduce creatinine levels; 6) Reduce amylase content; 7) Reduce the content of non-esterified fatty acids; 8) Increase glucagon levels; 9) Increase insulin levels; 10) Increase fructosamine content.

10. The application as described in claim 7, characterized in that, The dosage of the compound preparation is 200-300 mL / time / day, and the course of treatment is ≥3 days.

Images